Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs ANB 020 (Primary)
- Indications Peanut hypersensitivity
- Focus Proof of concept; Therapeutic Use
- Sponsors AnaptysBio
- 07 Nov 2017 According to an AnaptysBio media release, as of October 31, 2017, 75 percent of the study has been enrolled and the top-line data are expected in the first quarter of 2018.
- 11 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 11 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.